Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
15 Dec 2017
Change (% chg)

$0.06 (+4.20%)
Prev Close
$1.43
Open
$1.43
Day's High
$1.50
Day's Low
$1.43
Volume
11,600
Avg. Vol
29,162
52-wk High
$4.83
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Tuesday, 12 Dec 2017 08:00am EST 

Dec 12 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA.CARDIOME PHARMA CORP - AFFILIATE CORREVIO HAS ENTERED INTO AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WITH ZAO FIRMA EUROSERVICE.CARDIOME PHARMA - AS PER LICENSE AGREEMENT, ZAO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS FOR AGGRASTAT FROM RUSSIA'S MINISTRY OF HEALTH.CARDIOME PHARMA CORP - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Cardiome Q3 loss per share $0.20
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Cardiome Pharma Corp :Cardiome reports third quarter 2017 financial results.Sees fy 2017 revenue $24 million to $26 million.Q3 revenue $6.0 million versus I/B/E/S view $7.3 million.Q3 loss per share $0.20.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Cardiome Pharma Corp - expects existing cash and cash equivalents will be sufficient to fund its operations for at least next 12 months..  Full Article

Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Cardiome Pharma Corp -:Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​.  Full Article

Cardiome announces agreement with Basilea
Tuesday, 12 Sep 2017 07:01am EDT 

Sept 12 (Reuters) - Cardiome Pharma Corp ::Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel.Cardiome Pharma- under agreement, Basilea has granted cardiome an exclusive license to commercialize Ceftobiprole in 34 European countries and Israel.Cardiome Pharma Corp - Cardiome will provide Basilea with upfront payment, additional milestone payments based upon achievement of certain milestones.  Full Article

Cardiome provides U.S. regulatory update for BRINAVESS
Monday, 21 Aug 2017 08:00am EDT 

Aug 21 (Reuters) - Cardiome Pharma Corp :Cardiome provides U.S. regulatory update for BRINAVESS.Cardiome Pharma Corp - ‍FDA advised Cardiome that data package proposed by Cardiome would not be sufficient to support a resubmission of BRINAVESS NDA​.Cardiome Pharma Corp - ‍Intends to explore every reasonable avenue available to make Vernakalant available in United States​.Cardiome Pharma Corp - ‍"We will continue to have a dialogue with FDA as we review our regulatory options" for BRINAVESS​.  Full Article

Cardiome Pharma Q2 loss per share $0.26
Tuesday, 8 Aug 2017 04:02pm EDT 

Aug 8 (Reuters) - Cardiome Pharma Corp :Cardiome reports second quarter 2017 financial results.Q2 revenue $5.8 million versus I/B/E/S view $7.1 million.Q2 loss per share $0.26.Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Cardiome Pharma reports quarterly loss per share $0.26
Tuesday, 8 Aug 2017 04:00pm EDT 

Aug 9 (Reuters) - Cardiome Pharma Corp -:Qtrly loss per share $ 0.26.Qtrly revenues $5.8 million versus. $5.9 million.Q2 earnings per share view $-0.17, revenue view $7.1 million -- Thomson Reuters I/B/E/S.  Full Article

Cardiome Pharma announces Health Canada approval of AGGRASTAT high dose bolus regimen
Monday, 17 Jul 2017 08:00am EDT 

July 17 (Reuters) - Cardiome Pharma Corp :Cardiome announces Health Canada approval of Aggrastat high dose bolus regimen.Cardiome Pharma - ‍therapeutic Products Directorate of Health Canada approved aggrastat 25 mcg/kg (high) dose bolus regimen as requested under co SNDS​.  Full Article

Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT
Monday, 3 Jul 2017 08:00am EDT 

July 3 (Reuters) - Cardiome Pharma Corp :Cardiome's partner steadymed submits u.s. New drug application for trevyent® for the treatment of pulmonary arterial hypertension.Cardiome pharma corp - cardiome expects to file trevyent for european medicines agency and health canada approval by end of 2017..  Full Article

Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel
Wednesday, 21 Jun 2017 08:00am EDT 

June 21 (Reuters) - Cardiome Pharma Corp :Cardiome announces licensing agreement for xydalba™ (dalbavancin hydrochloride) to support planned commercialization in Israel.Cardiome Pharma Corp - signed an exclusive license and distribution agreement with tzamal medical ltd..Cardiome Pharma Corp - tzamal will be responsible for obtaining regulatory and pricing approvals for xydalba from israel's ministry of health.Cardiome Pharma - cardiome will receive an upfront payment, as well as additional payments, based upon commercial achievements and sales of xydalba.Cardiome Pharma Corp - additional terms were not disclosed.  Full Article